Amedisys Hospice An Adventa Company Medicare Approved Location: 1420 Dutch Valley Road, Suite C, Knoxville, Tennessee 37918 Phone: (865) 689-7123 |
Covenant Hospice Medicare Approved Location: 3001 Lake Brook Blvd Suite 101, Knoxville, Tennessee 37909 Phone: (423) 374-0600 |
Utmc Home Care Services-hospice Medicare Approved Location: 4435 Valley View Drive, Suite 103, Knoxville, Tennessee 37917 Phone: (865) 544-6222 |
Tennova Healthcare Hospice Medicare Approved Location: 7447 Andersonville Pike, Knoxville, Tennessee 37938 Phone: (865) 925-5500 |
Caris Healthcare Medicare Approved Location: 10651 Coward Mill Rd Suite B, Knoxville, Tennessee 37931 Phone: (865) 694-4848 |
News Archive
New research released today at the American Public Health Association's 140th Annual Meeting in San Francisco builds on previous knowledge about the link between teen pregnancy and social inequities internationally and suggests that, independent of other factors, low literacy in pre-teen girls strongly predicts childbearing among US teens.
DiagnoCure, Inc., a life sciences company that develops and commercializes highâvalue cancer diagnostic tests, announced today that Gen-Probe Incorporated, its commercial partner for the PCA3 test, received notice from the U.S. Food and Drug Administration (FDA) that the PROGENSA PCA3 Assay will not be reviewed by the Immunology Panel of FDA's Medical Devices Advisory Committee on October 14, 2011 as previously scheduled, but will be reviewed by the Panel at a later date.
HealthInfoNet, the nonprofit organization managing the Health Information Exchange for the State of Maine, today announced that it is partnering with Health Language, Inc., the global leader in medical terminology management, as it transitions from a two-year demonstration project to a full statewide HIE implementation. Health Language will support the Maine HIE's clinical content integration strategy during this expansion.
Actinic keratoses are sun-damaged rough patches or lesions on the skin - often pink and scaly - that doctors have long believed can turn into a form of skin cancer known as squamous cell carcinoma.
Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.
› Verified 7 days ago